Adenosine receptors as therapeutic targets

Nature Reviews. Drug Discovery
Kenneth A Jacobson, Zhan-Guo Gao

Abstract

Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.

Associated Clinical Trials

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Q Y ZhouO Civelli
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S FerreK Fuxe
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·C LondosJ Wolff
Apr 1, 1995·Naunyn-Schmiedeberg's Archives of Pharmacology·A J SzentmiklósiJ Z Szabó
Apr 1, 1995·Annals of Medicine·T GordhJ Kristensen
Jun 23, 1995·The Journal of Biological Chemistry·S Offermanns, M I Simon
Sep 22, 1994·European Journal of Pharmacology·D K Von LubitzK A Jacobson
Mar 1, 1995·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L BelardinelliM Srinivas
Jan 1, 1994·British Journal of Pharmacology·M C Peakman, S J Hill
Mar 2, 1994·Biochemical Pharmacology·L E Brackett, J W Daly
Feb 27, 1996·Biochemical and Biophysical Research Communications·Y KohnoK A Jacobson
Jul 1, 1996·British Journal of Pharmacology·A K DixonT C Freeman
Dec 1, 1995·Molecular Pharmacology·M P AbbracchioF Cattabeni
Dec 5, 1996·European Journal of Pharmacology·D K Von LubitzK A Jacobson
May 23, 1997·Science·T Porkka-HeiskanenR W McCarley
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·G P MatherneJ P Headrick
Nov 14, 1997·The Journal of Experimental Medicine·M C MontesinosB N Cronstein
Mar 17, 1998·Journal of Molecular and Cellular Cardiology·N S GauthierG P Matherne
Jul 3, 1998·European Journal of Pharmacology·J Sawynok
Jul 4, 1998·Trends in Pharmacological Sciences·K A Jacobson
Aug 1, 1998·European Journal of Pharmacology·S SatohO Hayaishi
Apr 15, 1999·Journal of the American Society of Nephrology : JASN·C S WilcoxL Belardinelli
Sep 10, 1999·Journal of Medicinal Chemistry·L J KnutsenM J Sheardown
Sep 29, 1999·Progress in Neurobiology·P SvenningssonB B Fredholm
Jan 21, 2000·Hypertension·R K DubeyE K Jackson
Feb 8, 2000·The Journal of Biological Chemistry·C A SalvatoreM A Jacobson
Feb 17, 2000·The Journal of Clinical Investigation·S L TilleyB H Koller
Mar 11, 2000·American Journal of Physiology. Renal Physiology·H T Lee, C W Emala
Mar 18, 2000·Pharmacology & Therapeutics·M E Olah, G L Stiles
May 20, 2000·JAMA : the Journal of the American Medical Association·G W RossL R White

❮ Previous
Next ❯

Citations

Oct 15, 2008·Archives of Internal Medicine·Ken IshitaniShumin M Zhang
Jan 24, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Harry Karmouty-QuintanaMichael R Blackburn
Jan 23, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Holger K Eltzschig
Jan 22, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Michail Sitkovsky, Akio Ohta
Jan 18, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Kyle JensenKarl-Norbert Klotz
Dec 7, 2007·Pflügers Archiv : European journal of physiology·Ivana NovakMette R Hansen
Apr 12, 2008·Purinergic Signalling·Stefania GessiPier Andrea Borea
Apr 12, 2008·Purinergic Signalling·Maria P Abbracchio, Stefania Ceruti
Mar 28, 2008·Purinergic Signalling·I Novak
Apr 30, 2008·Purinergic Signalling·Pier Giovanni BaraldiDelia Preti
Apr 29, 2008·Purinergic Signalling·Michael B HovaterErik M Schwiebert
Jul 8, 2008·Purinergic Signalling·Fievos Leontiou Christofi
Jul 11, 2008·Purinergic Signalling·Anikó Göblyös, Ad P Ijzerman
Sep 9, 2008·Purinergic Signalling·Benjamin GrauHartmann Harz
Feb 3, 2009·Purinergic Signalling·Pier Giovanni BaraldiDelia Preti
Nov 26, 2010·Purinergic Signalling·Mark WallNicholas Dale
Sep 2, 2010·Purinergic Signalling·Srdjan M VlajkovicPeter R Thorne
Jul 28, 2011·Purinergic Signalling·Marek CieślakMichał Komoszyński
Mar 1, 2012·Purinergic Signalling·Kenneth A JacobsonZhan-Guo Gao
Jul 19, 2012·Purinergic Signalling·Sérgio José Macedo-JuniorAdair Roberto Soares Santos
Sep 4, 2008·Current Heart Failure Reports·Stephen S Gottlieb
Sep 13, 2012·Immunologic Research·Sean P ColganEric L Campbell
Apr 27, 2011·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Erin C GradyRobert H Wagner
Feb 5, 2013·Neurochemistry International·Jacqueline A HubbardDevin K Binder
Feb 7, 2013·Neurochemistry International·Eleonora AronicaDetlev Boison
Mar 19, 2013·Trends in Endocrinology and Metabolism : TEM·Aránzazu Mediero, Bruce N Cronstein
Apr 13, 2007·Parasitology·F AngelucciC Valle
Mar 16, 2012·Analytical Chemistry·Emmanuel S BurgosVern L Schramm
Apr 13, 2011·Biochemistry·David RodríguezHugo Gutiérrez-de-Terán
Jun 1, 2012·Journal of Chemical Information and Modeling·Eelke van der HorstAdriaan P Ijzerman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.